Skip to content

Galera Therapeutics, Inc.

GRTX

CIK 0001563577

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$5.66M
+886.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.03
+288.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$19.81M
Q1 May 2026
Cash
$5.5M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
160.43M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings